3.70
+0.27(+7.87%)
Currency In USD
| Previous Close | 3.43 |
| Open | 3.63 |
| Day High | 4 |
| Day Low | 3.57 |
| 52-Week High | 58.24 |
| 52-Week Low | 2.22 |
| Volume | 154,043 |
| Average Volume | 514,960 |
| Market Cap | 2.12M |
| PE | -0.1 |
| EPS | -37.38 |
| Moving Average 50 Days | 4.65 |
| Moving Average 200 Days | 13.2 |
| Change | 0.27 |
If you invested $1000 in Indaptus Therapeutics, Inc. (INDP) 10 years ago, it would be worth $0.29 as of October 19, 2025 at a share price of $3.7. Whereas If you bought $1000 worth of Indaptus Therapeutics, Inc. (INDP) shares 5 years ago, it would be worth $6.85 as of October 19, 2025 at a share price of $3.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Indaptus Therapeutics Provides Clinical Update
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSW
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 8:05 PM GMT
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Confere
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
GlobeNewswire Inc.
Jul 01, 2025 12:14 PM GMT
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sal